Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for protein-protein interfaces.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the target protein, both isolated and in complex with key partner proteins, complemented by ensemble virtual screening that accounts for conformational mobility in the unbound and complex states. The tentative binding sites are explored on the protein-protein interaction interface and at remote allosteric locations, encompassing the entire spectrum of potential mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q16637
UPID:
SMN_HUMAN
Alternative names:
Component of gems 1; Gemin-1
Alternative UPACC:
Q16637; A8K0V4; Q13119; Q549U5; Q96J51
Background:
The Survival Motor Neuron (SMN) protein, also known as Gemin-1, plays a pivotal role in the assembly of small nuclear ribonucleoproteins (snRNPs), essential for pre-mRNA splicing. Its function is crucial in the spliceosome's formation, impacting cellular RNA processing and gene expression regulation.
Therapeutic significance:
Mutations in SMN1 are directly linked to Spinal Muscular Atrophy (SMA), a neuromuscular disorder with varying degrees of severity. Understanding the role of Survival Motor Neuron protein could open doors to potential therapeutic strategies for SMA, offering hope for targeted treatments.